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Introduction
Breast cancer is predicted to be newly diagnosed in about
211,300 women in 2003 in the United States [1,2].
Twelve percent of all women will be diagnosed with breast
cancer in their lifetime, and 3.5% will die of the disease.
The cell transformation associated with breast cancer
requires the coordinated activation or inhibition of specific
intact or altered genes. Transcription factors frequently
regulate these processes. An important type of transcrip-
tion factor contains a conserved region of 60 amino acids
called the homeodomain (HD), encoded by a DNA region,
the homeobox (HB). HD proteins are involved in the
control of development and differentiation in many organ-
isms [3,4]. Initially discovered in Drosophila, mutations of
DCIS = ductal carcinoma in situ; ER = estrogen receptor; HB = homeobox; HD = homeodomain; PR = progesterone receptor; RT–PCR = reverse
transcription polymerase chain reaction.
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Abstract
Background: BP1 is a novel homeobox gene cloned in our
laboratory. Our previous studies in leukemia demonstrated that
BP1 has oncogenic properties, including as a modulator of cell
survival. Here BP1 expression was examined in breast cancer,
and the relationship between BP1 expression and clinico-
pathological data was determined.
Methods: Total RNA was isolated from cell lines, tumors, and
matched normal adjacent tissue or tissue from autopsy.
Reverse transcription polymerase chain reaction was
performed to evaluate BP1 expression. Statistical analysis was
accomplished with SAS.
Results: Analysis of 46 invasive ductal breast tumors
demonstrated BP1 expression in 80% of them, compared with a
lack of expression in six normal breast tissues and low-level
expression in one normal breast tissue. Remarkably, 100% of
tumors that were negative for the estrogen receptor (ER) were
BP1-positive, whereas 73% of ER-positive tumors expressed
BP1 (P=0.03). BP1 expression was also associated with race:
89% of the tumors of African American women were
BP1-positive, whereas 57% of those from Caucasian women
expressed BP1 (P=0.04). However, there was no significant
difference in BP1 expression between grades I, II, and III tumors.
Interestingly, BP1 mRNA expression was correlated with the
ability of malignant cell lines to cause breast cancer in mice.
Conclusion: Because BP1 is expressed abnormally in breast
tumors, it could provide a useful target for therapy, particularly
in patients with ER-negative tumors. The frequent expression of
BP1 in all tumor grades suggests that activation of BP1 is an
early event.
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the HB in homeobox genes result in vast morphologic
abnormalities [3]. Subsequently, homologous HB genes
have been cloned in many species including humans [5–7].
Vertebrate HB genes are divided into two classes: Class I
genes (HOX genes) are organized into four clusters (HOX
A, B, C, D) with a total of 39 members [8]. Members of
Class II are also called divergent genes, including genes
such as PAX, MSX, IRX, and DLX, named after their
homologs in Drosophila (paired, muscle segment, Iro-
quois, and distal-less, respectively) [9,10]. Accumulating
evidence suggests that homeobox genes are important in
malignant transformation. Not only have altered expression
levels of HB genes been detected in a variety of human
malignancies [8,11–14], but the ectopic expression of
certain HOX genes can induce tumors [15–17]. Abnormal
HOX gene expression has been associated with breast
cancer. For example, the murine Hoxa-1 gene is upregu-
lated in neoplastic murine mammary glands [18]. In
humans, the lack of HOXA5 expression results in the loss
of p53 expression in breast cancer [19]. Enforced
HOXB7 expression in SkBr3 breast cancer cells induces
the expression of basic fibroblast growth factor and
increases growth rate, serum-independent growth, and
the ability of cells to form colonies in semisolid medium
[20]. Nude mice, when injected with SkBr3/HOXB7 cells,
developed tumors [21].
We have cloned a human homeobox cDNA called BP1,
belonging to the DLX family. BP1 is apparently involved in
the regulation of diverse pathways. In normal erythroid cells
it acts as a repressor of the β-globin gene [22,23].
However, BP1 was also expressed in 47% of the adult and
81% of the pediatric acute myeloid leukemia patients we
examined, and its overexpression increased the leuke-
mogenic potential of K562 cells in vitro [11]. Molecular
analysis revealed that BP1 expression is required for the
survival of K562 leukemia cells, suggesting that BP1 might
be part of an anti-apoptotic pathway (Davenport GJ, Fu S,
Haga SB, Do K, Stevenson H, Pinzone J, Chase MB, Berg
PE, unpublished data). Furthermore, these results imply
that aberrant BP1 expression might also be involved in
other malignancies. In the present study we analyzed BP1
expression in human breast cancer cell lines and assessed
BP1 expression in invasive ductal carcinoma tumors, corre-
lating its expression with age, tumor size, lymph node
metastasis, histologic grade, estrogen receptor (ER)
status, progesterone receptor (PR) status, and race.
Methods
Cell lines
The breast cancer cell lines Hs578T, MCF7, MDA-MB-231,
MDA-MB-468, and T-47D were kindly given to us by
Dr Angela Brodie; MCF7ADR and MDA-MB-435S were a
gift from Dr Joseph Fontana; and MCF10A was purchased
from the American Type Culture Collection (ATCC;
Manassas, VA, USA). Cell lines were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
calf serum, except for MCF10A cells, which were grown
as recommended by the ATCC.
Human breast tissues
Human breast tumor samples were obtained from The
George Washington University Department of Pathology
and the NCI Cooperative Human Tissue Network, South-
ern Division, all with Institutional Review Board approval,
and as previously described [24]. Breast tissue samples,
0.5–1.0cm in diameter, were obtained from fresh surgical
resection specimens from patients with breast tumors, and
were characterized pathologically in terms of their stage in
malignancy. The samples were snap-frozen in liquid nitro-
gen and were kept frozen until use. Normal breast tissues
were obtained from the periphery of specimens surgically
resected for treatment of cancer or from an autopsy speci-
men obtained from a patient who had died of injuries sus-
tained in an accident (not breast cancer); the latter was
obtained from the Brain and Tissue Bank for Developmen-
tal Disorders at the University of Maryland.
RNA isolation and reverse transcription polymerase
chain reaction (RT–PCR)
Total RNA was extracted from human breast cell lines,
frozen breast tumor tissues and normal breast tissues with
Trizol reagent (Invitrogen, Gaithersburg, MD, USA) in
accordance with the manufacturer’s protocol. Total RNA
(1µg) was used to synthesize cDNA with a SuperScript II
reverse transcriptase system (Invitrogen). After synthesis
of the first-strand cDNA, PCR was performed by initial
denaturing at 94°C for 2 min followed by 28 cycles of
denaturation at 94°C for 1 min, annealing at 60°C for
1 min, and extension at 72°C for 1.5 min. The PCR
primers for BP1, which span an intron, were 5′-GTATG-
GCCACCTCCTGTCTT-3′ (forward) and 5′-GAGTA-
GATGGTCCTCGGCTT-3′ (reverse), giving a product of
225 base pairs. The internal control for all samples was
β-actin.
Statistical analyses
Statistical analyses were used to determine the relation-
ship between BP1 positivity, measured by RT–PCR, and
clinico-pathological parameters. All P values were calcu-
lated with Fisher’s Exact Test. Tests were considered sig-
nificant if their associated P value was 0.05 or less
(two-tailed). All statistical analyses were performed with
SAS 8.2 (SAS Institute, Cary, NC, USA).
Results
BP1 expression in breast cell lines
BP1 mRNA levels were analyzed in a series of breast cell
lines by using RT–PCR. The cell lines are derived from
breast cancer patients, with the exception of MCF10A,
which is an immortalized, non-transformed epithelial cellBreast Cancer Research    Vol 5 No 4 Fu et al.
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line [25]. As shown in Fig.1, the levels of BP1 expression
varied widely between the cell lines, from barely
detectable (Hs578T, MDA-MB-435S, and MCF10A;
lanes 2, 6, and 9, respectively) to highly expressing
(MCF7ADR, MDA-MB-468, and T-47D; lanes 4, 7, and 8,
respectively); MCF7 and MDA-MB-231 (lanes 3 and 5,
respectively) showed intermediate expression. For com-
parison, one normal breast tissue from an autopsy was
included in the first lane; it was BP1-negative.
There was a correlation between BP1 expression and
tumorigenesis in mice (Table 1). The cell lines that express
little or no BP1 (Hs578T, MDA-MB-435S, and MCF10A)
are not tumorigenic, whereas MCF7ADR, MDA-MB-468,
and MDA-MB-231 express BP1 and are tumorigenic.
MCF7 and T-47D cells express variable BP1 levels and
are tumorigenic only in the presence of estradiol [26,27].
BP1 expression might therefore be involved in tumorigen-
esis in mice. Transgenic studies would provide direct evi-
dence for this hypothesis.
BP1 expression in breast tumor tissues
BP1 mRNA expression was examined in 46 invasive
ductal breast tumors including grades I, II, and III tumors
and, in some cases, compared with adjacent normal
breast tissue. Of these tumors, 80% expressed BP1. In
contrast, of seven normal breast tumors analyzed, six were
BP1-negative and one showed low BP1 expression. A
representative RT–PCR analysis of five tumors, three with
matched normal tissue, is shown in Fig.2. All of the tumors
shown are ER-negative and PR-negative. Matched normal
and tumor tissues from three patients are shown in lanes 1
and 2 (patient 1), 3 and 4 (patient 2), and 5 and 6
(patient 3). No BP1 expression was seen in the normal
samples (lanes 1, 3, and 5), whereas BP1 was expressed
in all of the tumors (lanes 2, 4, and 6). Two additional
tumor tissues, shown in lanes 7 and 8, were positive for
BP1; matched samples were not available.
Figure 1
Expression of BP1 in breast cancer cell lines. Reverse transcription
polymerase chain reaction was performed to analyze relative BP1
mRNA expression in cell lines and in one normal breast tissue. 
The loading control was β-actin.
BP1
β-actin
Normal Tissue
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MDA-MB-468
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Table 1
BP1 expression in breast cancer cell lines
Cell line ER PR Malignancy Tumorigenic* BP1
Hs578T – – Ductal carcinoma No +/–
MCF7 + + Adenocarcinoma † ++
MCF7ADR‡ ADR-resistant Yes +++
MDA-MB-231 – – Adenocarcinoma Yes ++
MDA-MB-435S – – Ductal carcinoma No +/–
MDA-MB-468 – – Adenocarcinoma Yes +++
T-47D + + Ductal carcinoma † +++
MCF10A + + Normal No +/–
*Data from the American Type Culture Collection, except for T-47D [22,23]. †Not tumorigenic without the addition of estradiol. ‡Non-responsive to
estradiol. ADR, adriamycin; ER, estrogen receptor; PR, progesterone receptor.
Figure 2
Expression of BP1 in breast tumors. Relative levels of BP1 mRNA
were determined by analysis of breast ductal tumors (T) or normal
controls (N) by reverse transcription polymerase chain reaction. The
loading control was β-actin.
N      T      N       T      N       T      T      T
BP1
β-actin
1       2       3        4       5       6       7       8To determine the significance of BP1 expression in the
tumor tissues, clinico-pathological data were related to
BP1 expression (Table 2). No significant relationship was
detected between BP1 status and age, tumor size, or
lymph node metastasis. Because 5-year survival data were
not available for some patients, we were not able to evalu-
ate survival outcome. BP1 expression was significantly
more prevalent in ER-negative tumors, of which 100%
were BP1-positive, compared with ER-positive tumors, of
which 73% were BP1-positive (P=0.03). There was also
a significant difference in BP1 expression between
PR-negative tumors, of which 96% were BP1-positive,
and PR-positive tumors, of which 67% were BP1-positive
(P=0.02). BP1 expression was associated with race: it
was expressed in 89% of the tumors of African American
women but in only 57% of the tumors of Caucasian
women (P=0.04). There was no significant difference in
BP1 expression between the three tumor grades: BP1
was expressed in 80% of grade I tumors, 73% of grade II
tumors and 90% of grade III tumors.
Discussion
In the present study we found that 80% of invasive ductal
breast tumors expressed BP1, a member of the DLX
homeobox gene family. In contrast, only 14% of normal
breast tissues expressed BP1. Our previous studies
showed that BP1 is also expressed in leukemia and has
characteristics of an oncogene: in acute myeloid leukemia,
BP1 is highly expressed in the bone marrow of 63% of
patients overall, with a preponderance of expression in
pediatric patients [11]. When overexpressed in a leukemia
cell line (K562), BP1 increased the ability of cells to grow
in soft agar, an indicator of leukemogenic potential, up to
45-fold [11]. Consistent with a possible oncogenic role for
BP1 in breast cancer was the observation that its expres-
sion was correlated with the ability of breast cancer cell
lines to cause mammary tumors in mice.
Recent studies have shown that abrogation of BP1
expression in a leukemia cell line leads to apoptosis
(Davenport GJ, Fu S, Haga SB, Do K, Stevenson H,
Pinzone J, Chase MB, Berg PE, unpublished data).
Coupled with the increased clonogenicity resulting from
overexpression of BP1, these observations suggest that
the expression of BP1 in breast tissue might also lead to
increased survival and, conversely, that the abrogation of
BP1 expression in malignant breast tissue could cause
apoptosis of those cells expressing BP1.
Estrogen and progesterone, which stimulate the growth of
breast epithelium, are two crucial hormones involved not
only in normal breast development but also in carcinogen-
esis of breast epithelium and progression of breast cancer
[28]. About 40% of breast cancers are ER-negative [28].
ER-negative tumors are unresponsive to anti-estrogen
therapy, probably because of constitutive growth factor
expression [28,29]. In general, these tumors have a higher
histologic grade and a higher proliferative rate and are
associated with poorer prognosis [28]. The finding that
100% of ER-negative tumors expressed BP1 might there-
fore be highly relevant to both the prognosis and therapy
of those difficult-to-treat tumors.
It is well known that African American women have a
higher mortality rate from breast cancer than Caucasian
women (reviewed by Mancino and colleagues [30]).
Although socioeconomic factors account for some of this
difference, several recent studies have shown that the
median survival of African American women presenting
Available online http://breast-cancer-research.com/content/5/4/R82
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Table 2
Association between BP1 mRNA expression and clinico-
pathological data
BP1 mRNA
Factors Negative Positive P
Age 1.00
Premenopausal 2 (17%) 10 (83%)
(<50 years)
Postmenopausal 7 (21%) 26 (79%)
(≥50 years)
Tumor size 1.00
<2.0cm 1 (17%) 5 (83%)
≥2.0cm 7 (19%) 30 (81%)
Lymph node metastasis 1.00
Negative 4 (20%) 16 (80%)
Positive 4 (18%) 18 (82%)
Histologic grade 0.29
I 1 (20%) 4 (80%)
II 4 (27%) 11 (73%)
III 2 (9%) 20 (91%)
ER status 0.03
Negative 0 (0%) 18 (100%)
Positive 7 (27%) 19 (73%)
PR status 0.02
Negative 1 (4.0%) 24 (96%)
Positive 6 (33%) 12 (67%)
Race 0.04
Caucasian 6 (43%) 8 (57%)
African American 3 (11%) 25 (89%)
ER, estrogen receptor; PR, progesterone receptor. Data were
unavailable or indeterminate for parameters as follows: age (one
tumor), tumor size (three tumors), lymph node metastasis (four tumors),
histologic grade (four tumors), ER status (two tumors), PR status
(three tumors), and race (four tumors).with Stage III or IV disease was significantly lower than
that of Caucasian women diagnosed at the same stage of
disease: in Stage III disease the median survival was 91.3
months for Caucasian patients and only 36.0 months for
African American patients, whereas in Stage IV disease
the median survival was reduced to 24.0 months for Cau-
casian patients and 8.9 months for African American
patients [30,31]. African American women also have a
higher risk of ER-negative tumors after adjustment is made
for stage and age at diagnosis. These results have led to
speculation that there could be biological differences
between African American and Caucasian women that
contribute to the differences in outcome. Interestingly,
more African American women than Caucasian women
were BP1-positive (P=0.04). It will be important to
expand further the number of women studied to determine
whether BP1 expression might be one biological factor
that underlies survival differences between African Ameri-
can and Caucasian women.
Because BP1 was expressed in all tumor grades, we
propose that it is activated in an early stage of malignant
development or even in a premalignant state. We have
therefore begun to examine ductal carcinoma in situ
(DCIS), which are preinvasive malignant lesions derived
from epithelial cells, and fibroadenomas, which are non-
malignant tumors composed of epithelial and stromal cells
[32,33]. So far we have analyzed one DCIS, which was
BP1-positive, and two fibroadenomas, both of which were
BP1-positive, compared with no expression in the matched
normal tissue for each fibroadenoma (data not shown). The
sample number is very small, but the fact that any of the
DCISs or fibroadenoma tumors are positive for BP1
demonstrates that activation of BP1 might be an early
event, perhaps promoting cell survival as seems to occur in
leukemia cells. This idea is also supported by the fact that
BP1 is as likely to be expressed in small tumors (less than
2.0cm) as it is in larger tumors (2.0cm or more).
The mechanism for overexpression of BP1 in breast cancer
is unknown. However, because of its map location at
17q21–22 [23], the BP1 gene is a potential candidate for
DNA amplification, which could lead to its activation or
overexpression. This hypothesis is based on the fact that
two regions on chromosome 17q are sometimes amplified
in breast cancer, one at 17q11–21 and another at
17q22–24 [34,35]. The locus of BP1 is also near BRCA1;
the implications of this proximity are not yet known.
To begin to identify genes that might be targets of BP1,
we have overexpressed BP1 in K562 cells and screened a
microarray (Davenport GJ, Fu S, Haga SB, Do K, Steven-
son H, Pinzone J, Chase MB, Berg PE, unpublished data).
Although K562 cells are derived from leukemia, among the
genes showing altered regulation were several that are
also dysregulated in breast cancer, including c-myc and
cyclin D2; their altered expression was verified by real-
time PCR. c-myc was upregulated in K562 cells overex-
pressing BP1, and c-Myc protein is highly expressed in
more than half of breast cancer patients [36]. Cyclin D2,
downregulated on the array, is repressed in breast cancer
[37]. It will be important to determine whether either of
those genes is a target for BP1 in breast cancer.
These data strongly implicate BP1 in breast cancer. More
case studies are underway to further strengthen our find-
ings and to determine whether there is a statistical associ-
ation between BP1 expression and prognosis or outcome
of breast cancer patients.
Conclusion
These data demonstrate a statistically significant associa-
tion between the expression of the transcription factor
BP1, not previously implicated in breast cancer, and
ER-negative breast tumors. This, together with other
studies, strongly suggests that BP1 has oncogenic prop-
erties, making it a new potential target in breast tumors,
especially the difficult-to-treat ER-negative tumors. Inter-
estingly, BP1 is expressed in 73–90% of tumors, includ-
ing all grades. This finding and the observation that
fibroadenomas (non-malignant tumors) can express BP1
strongly suggest that its activation might be associated
with loss of growth regulation, which is consistent with our
molecular data.
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